AI device being developed that can quickly tell if a mole is cancerous
A Toulouse-based start-up company called Pixience is using artificial intelligence to try to improve the diagnosis of skin cancer, drawing on machine learning to develop a device that it says could help healthcare professionals prioritise urgent cases.Like many countries around the world, including SA, France is grappling with a shortage of dermatologists. Patients currently wait on average 64 days for a consultation, according to Pixience’s Alexandre Delalleau.Pixience is developing a device that aims to quickly and reliably gauge whether patients have benign moles or malignant melanomas. If successful, a potential application would be to use it to screen patients who suspected they had skin cancer, and ensure the most urgent cases were placed at the front of the queue, said Delalleau."Our aim is to have high-quality screening available in pharmacies that will provide a severity grade for the lesion or mole and then refer the patient to the dermatologist, urgently or not. We don’t ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.